ArthroCare CE marks WoundWand
This article was originally published in Clinica
ArthroCare has CE marked its WoundWand debridement device for sale in Europe. The device removes dead or damaged tissue from a wound in a "precise and controlled manner", Austin, Texas-based ArthroCare says. Debridement is carried out in wounds that have not properly healed on their own, as the dead tissue can lead to infections and abscesses, as well as delaying healing further. The device employs the firm's Coblation technology, which uses low-temperature radiofrequency energy to dissolve rather than burn soft tissue, minimising damage to healthy tissue. WoundWand is not yet approved by the US FDA.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.